-
'Bad guys' among the antiparkinsonian drugsPirtošek, Zvezdan, 1956-The first effective drugs for Parkinson's disease (PD) were anticholinergics, introduced at the end of 19.th century by Charcot. Since the introduction of levodopa in the sixties of the previous ... century, many new drugs have emerged for the treatment of Parkinson's disease: dopamine agonists (ergot as well asnon-ergot, bromocriptine, pergolide, mirapexine, ropinirole), MAO B inhibitors (selegiline, rasagiline), amantadine, COMT inhibitors (entacapone, tolcapone). In all stages of the disease, levodopa remains the most effective drug for improving motor symptoms in PD. However, long term treatment with levodopa is accompanied by the development of motor fluctuations, dyskinesia, cognitive and neuropsychiatric adverse effects and increasingly diverse spectrum of drugs is needed to alleviate motor and nonmotor symptoms. Some of these drugs have caused considerable concern and controversies and were regarded at certain points as the 'bad guys' of Parkinson's disease pharmacological armamentarium. In the article, a short review of 'bad guys' including anticholinergics, selegiline, tolcapone and dopamine agonists, is given.Vir: 1st Croatian Congress on Side Effects of Psychotropics with international participants : Some Selected Papers and Abstracts, February 26th - March 1st 2009, Osijek, Croatia (str. 114-118)Vrsta gradiva - prispevek na konferenciLeto - 2009Jezik - angleškiCOBISS.SI-ID - 26254553
Avtor
Pirtošek, Zvezdan, 1956-
Teme
Antiparkinson Agents |
Adverse Effects |
Therapeutic Use |
Benzophenones |
Adverse Effects |
Therapeutic Use |
Cholinergic Antagonists |
Adverse Effects |
Therapeutic Use |
Cognition |
Drug Effects |
Dopamine Agonists |
Adverse Effects |
Therapeutic Use |
Levodopa |
Adverse Effects |
Therapeutic Use |
Nitrophenols |
Adverse Effects |
Therapeutic Use |
Parkinson Disease |
Drug Therapy |
Mortality |
Selegiline |
Therapeutic Use |
Adverse Effects |
Survival Rate |
Treatment Outcome |
Dopaminski agonisti |
Parkinsonova bolezen |
Benzofenoni |
Spoznava |
Levodopa |
Selegilin |
Preživetje, stopnja |
Zdravljenje, izid |
Antiparkinsoniki |
Holinergični antagonisti |
Nitrofenoli
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
| Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
|---|---|---|---|---|---|---|---|---|
| JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP | |
Faktor vpliva
Baze podatkov, v katerih je revija indeksirana
| Ime baze podatkov | Področje | Leto |
|---|
| Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
|---|---|
| Pirtošek, Zvezdan, 1956- | 05380 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
| Mesto prevzema | Status gradiva | Rezervacija |
|---|
Prosimo, počakajte trenutek.